The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,588,346 in first-year total cost, median $813,340.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRB-A (M1)]6
Most frequent institutions
- ST. JUDE CHILDREN'S RESEARCH HOSPITAL2
- CHILDREN'S HOSP OF PHILADELPHIA1
- DANA-FARBER CANCER INST1
- SEATTLE CHILDREN'S HOSPITAL1
- STANFORD UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma1U01CA281848-01 | KALIA, VANDANAOLSON, JAMES M | SEATTLE CHILDREN'S HOSPITAL, WA | $860,018 | ZCA1 |
| 2023 | Personalized neuroblastoma vaccines1U01CA281881-01 | MARIS, JOHN MSCHOENBERGER, STEPHEN PHILIP | CHILDREN'S HOSP OF PHILADELPHIA, PA | $839,128 | ZCA1 |
| 2023 | Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology1U01CA281868-01 | CHI, HONGBOYU, JIYANG | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $819,000 | ZCA1 |
| 2023 | Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma1U01CA281823-01 | KRENCIUTE, GIEDREMACK, STEPHEN CPHOENIX, TIMOTHY N | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $807,680 | ZCA1 |
| 2023 | Immunotherapeutic targeting of gangliosides in Ewing Sarcoma1U01CA281840-01 | MAJZNER, ROBBIE G.STEGMAIER, KIMBERLY | DANA-FARBER CANCER INST, MA | $795,150 | ZCA1 |
| 2023 | Attacking the Immunopeptidome of Ewing Sarcoma1U01CA281865-01 | HEITZENEDER, SABINEMACKALL, CRYSTAL | STANFORD UNIVERSITY, CA | $467,370 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.